Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9NO3.C6H12N4 |
Molecular Weight | 319.3589 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1N2CN3CN1CN(C2)C3.OC(=O)CNC(=O)C4=CC=CC=C4
InChI
InChIKey=ROAIXOJGRFKICW-UHFFFAOYSA-N
InChI=1S/C9H9NO3.C6H12N4/c11-8(12)6-10-9(13)7-4-2-1-3-5-7;1-7-2-9-4-8(1)5-10(3-7)6-9/h1-5H,6H2,(H,10,13)(H,11,12);1-6H2
Molecular Formula | C6H12N4 |
Molecular Weight | 140.1863 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C9H9NO3 |
Molecular Weight | 179.1727 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/24689705Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24689705
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Methenamine is an antibacterial agent for preventing recurrent urinary tract infection. It can be used as methenamine hippurate or methenamine mandelate preparations and is United States Food and Drug Administration-approved. Methenamine exerts its activity because it is hydrolyzed to formaldehyde in acid urine.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | UREX Approved UseFOR URAMIT MB™: URAMIT MB™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. Launch Date-7.8710399E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
177 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1 g 2 times / day multiple, oral Recommended Dose: 1 g, 2 times / day Route: oral Route: multiple Dose: 1 g, 2 times / day Sources: |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
1 g single, oral Recommended |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
Other AEs: Bladder irritation, Micturition painful... Other AEs: Bladder irritation Sources: Micturition painful Micturition frequency Albuminuria Hematuria |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Albuminuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Bladder irritation | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Hematuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition frequency | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition painful | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of Er:YAG laser and EDTAC on dentin adhesion of six endodontic sealers. | 2001 |
|
The lock-in phase in the urotropine-sebacic acid system. | 2001 Aug |
|
Developmental changes in the fine structure and histochemical properties of mucous cells in the parotid gland of the infant Japanese macaque. | 2001 Dec |
|
Antimicrobial activity of four root canal sealers against endodontic pathogens. | 2001 Dec |
|
Post retention: the effect of sequence of post-space preparation, cementation time, and different sealers. | 2001 Dec |
|
Evaluation of the genotoxicity of zinc oxide eugenol-based, calcium hydroxide-based, and epoxy resin-based root canal sealers by comet assay. | 2001 Dec |
|
Plaque-like structures and arteriosclerotic changes in "diffuse neurofibrillary tangles with calcification" (DNTC). | 2001 Dec |
|
Septum formation in Aspergillus nidulans. | 2001 Dec |
|
[An 84-year-old woman with progressive mental deterioration and abnormal behavior]. | 2001 Feb |
|
Localization of a mammalian homolog of diaphanous, mDia1, to the mitotic spindle in HeLa cells. | 2001 Feb |
|
Effect of ultrasonic vibration and various sealer and cement combinations on titanium post removal. | 2001 Jan |
|
Coordination of microtubules and the actin cytoskeleton by the Rho effector mDia1. | 2001 Jan |
|
Toward designed assembly of microporous coordination networks constructed from silver(I)-hexamethylenetetramine layers. | 2001 Jul 2 |
|
Setting times for endodontic sealers under clinical usage and in vitro conditions. | 2001 Jun |
|
Formaldehyde release from ground root canal sealer in vitro. | 2001 Jun |
|
A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. | 2001 Jun |
|
A primary observation on the preparation and obturation of oval canals. | 2001 Mar |
|
Oral exfoliative cytology in the diagnosis of paracoccidioidomycosis. | 2001 May-Jun |
|
Genes and proteins in renal development. | 2002 |
|
Methenamine hippurate for preventing urinary tract infections. | 2002 |
|
The evolutionary history of effectors downstream of Cdc42 and Rac. | 2002 |
|
Comparison of staining methods and a nested PCR assay to detect Histoplasma capsulatum in tissue sections. | 2002 Apr |
|
An actin nucleation mechanism mediated by Bni1 and profilin. | 2002 Aug |
|
Invasive Aspergillosis in Italian AIDS patients. | 2002 Dec |
|
Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes. | 2002 Dec |
|
A simple method for the specific detection of Ren-1 renin. | 2002 Dec |
|
Cytotoxicity of resin-, zinc oxide-eugenol-, and calcium hydroxide-based root canal sealers on human periodontal ligament cells and permanent V79 cells. | 2002 Feb |
|
Formin' actin filament bundles. | 2002 Feb |
|
Ground-glass hepatocytes in fibrinogen storage disease in Japanese Black calves. | 2002 Feb-Apr |
|
Effects of instrumentation, irrigation and dressing with calcium hydroxide on infection in pulpless teeth with periapical bone lesions. | 2002 Jan |
|
Hexamethylenetetraminium 2,4,6-trinitrophenolate. | 2002 Jan |
|
Formins direct Arp2/3-independent actin filament assembly to polarize cell growth in yeast. | 2002 Jan |
|
Evaluation of lectin staining in the diagnosis of fungal keratitis in an experimental rabbit model. | 2002 Jan 25 |
|
Monolithic scavenger resins by amine functionalizations of poly(4-vinylbenzyl chloride-co-divinylbenzene) PolyHIPE materials. | 2002 Jul 25 |
|
Role of formins in actin assembly: nucleation and barbed-end association. | 2002 Jul 26 |
|
Formins direct Arp2/3-independent actin filament assembly to polarize cell growth in yeast. | 2002 Mar |
|
Vibrational frequencies and structural determinations of hexamethylenetetraamine. | 2002 May |
|
Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). | 2002 May 22 |
|
Mutational analysis of human profilin I reveals a second PI(4,5)-P2 binding site neighbouring the poly(L-proline) binding site. | 2002 May 28 |
|
Dimethylsilane polyamines: cytostatic compounds with potentials as anticancer drugs. II. Uptake and potential cytotoxic mechanisms. | 2002 Nov-Dec |
|
Syntheses of two new 1D and 3D networks of Cu(II) and Co(II) using malonate and urotropine as bridging ligands: crystal structures and magnetic studies. | 2003 Apr 21 |
|
Crystallographic analysis of the thermal motion of the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with hexamethylenetetramine. | 2003 Feb 7 |
|
Adducts of hexamethylenetetramine with ferrocenecarboxylic acid and ferrocene-1,1'-dicarboxylic acid: multiple disorder in space groups Fmm2 and Cmcm. | 2003 Jul |
|
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. | 2003 Jul |
|
Structural changes of hexamethylenetetramine and undecanedioic acid co-crystal (HMT-C11) as a function of the temperature. | 2003 Jun |
|
Immunofluorescence of the epizootic ulcerative syndrome pathogen, Aphanomyces invadans, using a monoclonal antibody. | 2003 Jun 20 |
|
Detection of sugar syrups in apple juice by delta(2)H per thousand and delta(13)C per thousand analysis of hexamethylenetetramine prepared from fructose. | 2003 Mar 26 |
|
Glomerular lesions in dogs infected with Leishmania organisms. | 2003 May |
|
[Quantitative assessment of the biological activity of chemicals by soil microbial associations]. | 2003 May-Jun |
|
Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism. | 2003 Oct 3 |
Patents
Sample Use Guides
One tablet (1 g) twice daily for adults and children over 12 years of age. One-half tablet or one tablet (0.5 or 1 g) twice daily for children 6 to 12 years of age.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7028634
The antibacterial activity of methenamine and two of its organic acid salts was compared by continuous turbidimetric monitoring of static cultures exposed to the drugs and in an in vitro model of the treatment of bacterial cystitis. At pH 5.5, concentrations of 32 to 125 mg methenamine per 1 caused some inhibition of bacterial growth (Klebsiella aerogenes), but 250 to 500 mg/l were needed to suppress growth overnight. Methenamine hippurate was found to be less active than methenamine itself, whereas methenamine mandelate was as active as the parent compound.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:27:27 UTC 2022
by
admin
on
Fri Dec 16 16:27:27 UTC 2022
|
Record UNII |
M329791L57
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C255
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB14537MIG
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
5714-73-8
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
21945
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
DBSALT001270
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
M329791L57
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
DTXSID10972603
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
CHEMBL1201270
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
29652
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | RxNorm | ||
|
M329791L57
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
C011481
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
C47610
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
1409502
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
M7308
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | Merck Index | ||
|
Methenamine Hippurate
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY | |||
|
227-206-5
Created by
admin on Fri Dec 16 16:27:27 UTC 2022 , Edited by admin on Fri Dec 16 16:27:27 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |